2023 World Conference on Lung Cancer (Posters)-EP12.01. Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort

EP12.01. Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort - PDF(Abstract)

Back to course

Pdf Summary

This study analyzed the occurrence and effects of skin toxicity (Sk-Tox) associated with targeted and immune therapies in patients with stage IV non-small cell lung cancer (Stg4-NSCLC). A cohort of 3,768 Stg4-NSCLC patients diagnosed between 2006 and 2019 was followed through 2022. Of the 699 patients treated with targeted and immunotherapies, 50% experienced Sk-Tox. The most common Sk-Tox were rash, xerosis, pruritus, paronychia, and erythema, with rash occurring at a median of 21 days after drug initiation and paronychia at 65 days. Sk-Tox severity ranged from mild to life-threatening. Elotinib was the leading drug associated with Sk-Tox, followed by osimertinib, afatinib, bevacizumab, and cetuximab. Patients with Sk-Tox had a higher treatment response rate and longer median overall survival time compared to patients without Sk-Tox. Multivariable analysis showed smoking history, non-adenocarcinoma, surgery and/or combined therapy, and treatment response as independent prognostic factors for survival. The study also found that never smokers and patients with EGFR mutations were more likely to develop Sk-Tox. The authors concluded that Stg4-NSCLC patients who experienced Sk-Tox had better treatment response and survival outcomes. They emphasized the importance of collaboration between oncologists and dermatologists for the awareness, prevention, and treatment of Sk-Tox in these patients.

Asset Subtitle

Ping Yang

Meta Tag

Speaker Ping Yang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

skin toxicity

targeted therapies

immune therapies

non-small cell lung cancer

Stg4-NSCLC

rash

xerosis

pruritus

paronychia

erythema